Theriva Biologics Statistics
Share Statistics
Theriva Biologics has 2.78M
shares outstanding. The number of shares has increased by -83.9%
in one year.
| Shares Outstanding | 2.78M |
| Shares Change (YoY) | -83.9% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,397 |
| FTD / Avg. Volume | 4.48% |
Short Selling Information
The latest short interest is 96.65K, so 3.47% of the outstanding
shares have been sold short.
| Short Interest | 96.65K |
| Short % of Shares Out | 3.47% |
| Short % of Float | 3.49% |
| Short Ratio (days to cover) | 3.41 |
Valuation Ratios
The PE ratio is -0.09 and the forward
PE ratio is -0.23.
Theriva Biologics's PEG ratio is
0.
| PE Ratio | -0.09 |
| Forward PE | -0.23 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.12 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Theriva Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15,
with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.15 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,282,650 |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -92.37% in the
last 52 weeks. The beta is 1.15, so Theriva Biologics's
price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | -92.37% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 27.09 |
| Average Volume (20 Days) | 31,176 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.35M |
| Net Income | -25.65M |
| EBITDA | -25.52M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -19.03 |
Full Income StatementBalance Sheet
The company has 11.61M in cash and 1.56M in
debt, giving a net cash position of 10.04M.
| Cash & Cash Equivalents | 11.61M |
| Total Debt | 1.56M |
| Net Cash | 10.04M |
| Retained Earnings | -334.97M |
| Total Assets | 35.35M |
| Working Capital | 8.7M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -16.94M
and capital expenditures -1K, giving a free cash flow of -16.94M.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | -1K |
| Free Cash Flow | -16.94M |
| FCF Per Share | -12.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
